Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Get up to date with expert perspectives on how to best incorporate evolving guidelines and real-world data into care of patients with CLL using downloadable slides clinical commentary and on-demand webcast capturing a live NCCN/CCO webinar.

Management of Recurrent BC - Downloadable Slidesets - UC Novel Therapies - Oncology - Clinical Care Options (clinicaloptions.com)

Share

Program Content

Activities

Frontline Therapy for CLL
Optimal Selection of Therapy for Treatment-Naive CLL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2021

Expires: June 07, 2022

Treating R/R CLL
State of the Art Management in Relapsed/Refractory CLL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2021

Expires: June 07, 2022

Future Directions in CLL
Near Future Directions: Promising Agents and Combinations Under Investigation
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2021

Expires: June 07, 2022

<i>EP</i>: State-of-the-Art in CLL
ExpressPoints
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Expires: June 14, 2022

Activities

FAQs: CLL Management
Answers to Frequently Asked Questions on State-of-the-Art Management of CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2021

Expires: June 29, 2022

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BeiGene, Ltd.

Lilly

Pharmacyclics LLC and Janssen